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Background
The prognosis is poor for patients with cHL who relapse
after autologous stem-cell transplant (auto-SCT) or pro-
gress after brentuximab vedotin (BV) therapy. cHL fre-
quently harbors genetic amplification at 9p24.1, which
leads to overexpression of PD-L1 and PD-L2 on the
tumor cell surface. This suggests that cHL may have a
genetically determined dependence on the PD-1 path-
way for survival. Pembrolizumab is a humanized mono-
clonal antibody against PD-1 that is designed to block
the interaction of PD-1 with its ligands PD-L1 and
PD-L2. Based on the frequent expression of the ligands
on cHL, we sought to evaluate the safety and efficacy of
pembrolizumab for R/R cHL. In a Phase I study, pem-
brolizumab displayed high activity in cHL, with an over-
all response rate of 65% and complete response rate of
20% [1]. The present Phase II study was undertaken to
extend those findings in a larger cohort.
Methods
KEYNOTE-087 (NCT02453594) is a multicenter, non-
randomized, multicohort Phase II study comprising
patients with cHL who have failed to achieve a response
or progressed after auto-SCT and BV (cohort 1);
patients who are not eligible for auto-SCT and have
failed to achieve a response or progressed after BV
(cohort 2); and patients who have failed to achieve a
response or progressed after auto-SCT and have not
received BV after auto-SCT (cohort 3). Key eligibility
criteria include age ≥18 years, measurable disease,
ECOG performance status 0/1, and adequate organ
function. Exclusion criteria include immunosuppression,
allogeneic stem cell transplantation within 5 years, active
pneumonitis, and prior anti-PD-1/PD-L1 therapy. Treat-
ment with pembrolizumab IV 200 mg Q3W will con-
tinue for ≤24 months or until confirmed disease
progression, intolerable toxicity, or physician decision.
AEs are collected throughout the study and for 30 days
thereafter (90 days for serious AEs). Response is cen-
trally assessed every 12 weeks per 2007 IWG criteria.
Patients who achieve a complete response can discon-
tinue treatment and then be retreated at the time of
relapse. Primary efficacy end point is objective response
rate (ORR) using IWG criteria per central review sec-
ondary end points are ORR per investigator review,
ORR per central review using Lugano 5-point classifica-
tion, complete remission rate, duration of response, pro-
gression-free survival, and overall survival. Exploratory
end points include assessments of PK profile, relation-
ship between candidate efficacy biomarkers and antitu-
mor activity of pembrolizumab, and efficacy in patients
who continue pembrolizumab beyond documented pro-
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